Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1436-3305
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study ; volume:25 ; number:1 ; day:28 ; month:9 ; year:2021 ; pages:245-253 ; date:1.2022
Gastric cancer ; 25, Heft 1 (28.9.2021), 245-253, 1.2022
- Urheber
-
Yamaguchi, Kensei
Boku, Narikazu
Muro, Kei
Yoshida, Kazuhiro
Baba, Hideo
Tanaka, Shinji
Akamatsu, Ayumi
Sano, Takeshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10120-021-01244-y
- URN
-
urn:nbn:de:101:1-2022042300291686725074
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yamaguchi, Kensei
- Boku, Narikazu
- Muro, Kei
- Yoshida, Kazuhiro
- Baba, Hideo
- Tanaka, Shinji
- Akamatsu, Ayumi
- Sano, Takeshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery
Li Fraumeni Syndrome predisposes to gastro-esophageal junction tumours
A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Role of tight junction proteins in gastroesophageal reflux disease
Two decades of gastric and gastroesophageal junction cancer surgery